Nuvalent (NASDAQ:NUVL) Stock

Nuvalent

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Chicago,,Il,-,July,27,,2017:,American,Airlines,Plane,On

News

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ARQT

ARTV

CTXR

NUVL

This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

Stock market analysts

Initiation

MTVA

This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Bridgewater,,Nj,,Usa,-,August,23,,2022:,Bausch,Health,Us

Mid Cap

Movers

ASND

BLCO

EWTX

POWL

Federal Reserve&#39;s rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week.

Bausch &amp; Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?

Nuvalent Inc

Offerings

Press Releases

Nuvalent Announces Public Offering of Common Stock

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

Earnings

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nuvalent Appoints Grant Bogle to Board of Directors

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

NVCT

SMMT

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Akero Therapeutics

Alkermes

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biohaven

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

HC Wainwright & Co.

BMO Capital

JP Morgan

Guggenheim

Comments

Nuvalent

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga